-
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPROVAL OF ORAL SMALL MOLECULE 3CL PROTEASE INHIBITOR“HS-10517 TABLETS”AGAINST SARS-CoV-22023-01-17
-
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL NOTICE OF“HS-10390 TABLETS”2023-01-09
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 20222023-01-05
-
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL NOTICE OF“HS-10502 TABLETS”2022-12-28
-
Terms of Reference of the Remuneration Committee2022-12-05
-
VOLUNTARY ANNOUNCEMENT - EQRX'S MARKETING AUTHORIZATION APPLICATION FOR AUMOLERTINIB IN EGFR-MUTATED NON-SMALL CELL LUNG CANCER ACCEPTED BY THE EUROPEAN MEDICINES AGENCY (EMA)2022-12-02
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 20222022-12-02
-
VOLUNTARY ANNOUNCEMENT - LICENSING AGREEMENT WITH BIOTHEUS2022-11-14
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 20222022-11-03
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE RESTRICTED SHARE UNIT SCHEME2022-10-31
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 20222022-10-06
-
VOLUNTARY ANNOUNCEMENT - LICENSING AGREEMENT WITH KIOMED2022-09-26